Stockholm Region will deploy Lunit INSIGHT MMG as an independent second reader across three institutions—Capio Saint Gören Hospital, Karolinska University Hospital, and Södersjukhuset—expanding from a single hospital into a regional program.

Sectra’s enterprise imaging platform supports modular, scalable solutions and is recognized for reducing operational costs and high industry rankings.

Lunit AI will function as an independent reader for breast cancer screening throughout Stockholm County, scaling from one hospital to the entire regional program to boost throughput.

The rollout aims to normalize AI-based regional breast screening as standard infrastructure rather than a pilot, providing a concrete regional model for imaging software buyers.

Evidence from the ScreenTrustCAD study indicates that one radiologist plus AI detected more cancers than traditional double reading by two radiologists, with results published in The Lancet Digital Health and presented at RSNA.

The regional deployment builds toward sustained, population-based AI-assisted screening as a standard of care in Stockholm, reflecting a broader shift in imaging workflows.

Capio Saint Gören Hospital has used Lunit INSIGHT MMG for about 200,000 mammograms over the past three years, validating scalability amid changes in mammography systems.

AI readers in medical imaging are advancing diagnostic consistency, throughput, and population health initiatives across cancer diagnostics and hospital technology.

Three overarching themes emerge: AI as shared regional diagnostic infrastructure, second-reader automation to boost capacity, and scaled clinical AI deployment driven by real-world performance data.

The Stockholm rollout follows prior regional adoption in Dalarna and builds on ScreenTrustCAD’s prospective study at Saint Gören Hospital, which involved over 55,000 women.

Research and clinical use spanning 2021-2022, including collaboration with Karolinska Institutet and Capio S Gören Hospital, underpins the evidence base for the rollout.

Stockholm is positioned as a model for how clinically validated AI can enable large-scale, population-based breast cancer screening in Europe and beyond.